Published in Haematologica on December 14, 2012
Global cellular response to chemotherapy-induced apoptosis. Elife (2013) 1.19
Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma. Haematologica (2015) 0.81
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia (2015) 0.78
Cap dependent translation contributes to resistance of myeloma cells to bortezomib. Translation (Austin) (2013) 0.77
Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma. Leukemia (2016) 0.75
Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model. Oncotarget (2016) 0.75
New perspectives on the molecular basis of the interaction between oxygen homeostasis and iron metabolism. Hypoxia (Auckl) (2015) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Anemia of chronic disease. N Engl J Med (2005) 10.88
Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45
The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol (2006) 5.33
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood (2006) 5.21
Regulation of cellular iron metabolism. Biochem J (2011) 3.03
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Autocrine formation of hepcidin induces iron retention in human monocytes. Blood (2007) 2.50
Specific iron chelators determine the route of ferritin degradation. Blood (2009) 2.10
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood (2010) 2.03
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem (2000) 1.88
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood (2009) 1.77
Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J (2006) 1.66
Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol (2000) 1.58
Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta (2010) 1.39
Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol (2005) 1.38
Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal (2010) 1.35
Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2003) 1.26
Iron-dependent degradation of apo-IRP1 by the ubiquitin-proteasome pathway. Mol Cell Biol (2007) 1.25
Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J Biol Chem (2004) 1.12
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol (2008) 1.05
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest (1996) 1.00
Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem (2011) 0.98
Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis (2009) 0.94
Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid Redox Signal (2010) 0.94
Human iron transporters. Genes Nutr (2010) 0.93
Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol (2009) 0.92
Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol (2011) 0.85
Nitric oxide, proteasomal function, and iron homeostasis--implications in aging and neurodegenerative diseases. Methods Enzymol (2005) 0.82
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet (2002) 4.19
Iron-deficiency anemia. N Engl J Med (2015) 3.94
The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab (2008) 3.78
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
Protein quality control in the early secretory pathway. EMBO J (2008) 3.59
Hepcidin is decreased in TFR2 hemochromatosis. Blood (2004) 3.46
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood (2008) 2.71
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity (2003) 2.40
Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A (2002) 2.35
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood (2007) 2.09
Tyrosine kinase signal modulation: a matter of H2O2 membrane permeability? Antioxid Redox Signal (2013) 2.00
ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family. EMBO J (2002) 1.98
Thiol-mediated protein retention in the endoplasmic reticulum: the role of ERp44. EMBO J (2003) 1.96
Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol (2013) 1.85
Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood (2007) 1.78
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood (2009) 1.77
Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood (2009) 1.66
Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol (2010) 1.64
Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res (2007) 1.60
A pH-regulated quality control cycle for surveillance of secretory protein assembly. Mol Cell (2013) 1.60
Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol (2008) 1.60
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
Glutathione limits Ero1-dependent oxidation in the endoplasmic reticulum. J Biol Chem (2004) 1.58
Variation of hemoglobin levels in normal Italian populations from genetic isolates. Haematologica (2008) 1.57
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood (2013) 1.55
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Managing and exploiting stress in the antibody factory. FEBS Lett (2007) 1.48
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ and thioredoxin domains, is expressed in secretory cells or following ER stress. J Biol Chem (2002) 1.44
Sequential steps and checkpoints in the early exocytic compartment during secretory IgM biogenesis. EMBO J (2007) 1.43
Multistep, sequential control of the trafficking and function of the multiple sulfatase deficiency gene product, SUMF1 by PDI, ERGIC-53 and ERp44. Hum Mol Genet (2008) 1.43
Dynamic retention of Ero1alpha and Ero1beta in the endoplasmic reticulum by interactions with PDI and ERp44. Antioxid Redox Signal (2006) 1.42
Conditions of endoplasmic reticulum stress favor the accumulation of cytosolic prion protein. J Biol Chem (2006) 1.40
TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood (2011) 1.39
Defective targeting of hemojuvelin to plasma membrane is a common pathogenetic mechanism in juvenile hemochromatosis. Blood (2007) 1.36
Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica (2010) 1.36
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood (2013) 1.34
Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica (2006) 1.34
Towards explaining "unexplained hyperferritinemia". Haematologica (2009) 1.33
Crystal structures of human Ero1α reveal the mechanisms of regulated and targeted oxidation of PDI. EMBO J (2010) 1.33
Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest (2010) 1.32
Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood (2011) 1.31
A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood (2002) 1.31
Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet (2008) 1.30
Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet (2011) 1.28
The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol (2007) 1.27
Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J (2006) 1.27
CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. Mol Immunol (2009) 1.26
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Blood (2012) 1.25
Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood (2010) 1.23
Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem (2002) 1.22
Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis (2007) 1.20
Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood (2003) 1.20
Unique iron binding and oxidation properties of human mitochondrial ferritin: a comparative analysis with Human H-chain ferritin. J Mol Biol (2005) 1.20
The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast. Hum Mol Genet (2004) 1.19
Endoplasmic reticulum stress. Ann N Y Acad Sci (2007) 1.18
Peroxides and peroxidases in the endoplasmic reticulum: integrating redox homeostasis and oxidative folding. Antioxid Redox Signal (2012) 1.18
Ero1α regulates Ca(2+) fluxes at the endoplasmic reticulum-mitochondria interface (MAM). Antioxid Redox Signal (2011) 1.17
Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood (2005) 1.17
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res (2009) 1.16
Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology (2009) 1.15
Crystal structure and biochemical properties of the human mitochondrial ferritin and its mutant Ser144Ala. J Mol Biol (2004) 1.15
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res (2007) 1.13
Iron refractory iron deficiency anemia. Haematologica (2013) 1.13
ER storage diseases: a role for ERGIC-53 in controlling the formation and shape of Russell bodies. J Cell Sci (2006) 1.12
Ferrous ion binding to recombinant human H-chain ferritin. An isothermal titration calorimetry study. Biochemistry (2002) 1.12
Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability. Neoplasia (2002) 1.12
A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet (2013) 1.12
Two conserved cysteine triads in human Ero1alpha cooperate for efficient disulfide bond formation in the endoplasmic reticulum. J Biol Chem (2004) 1.11
Heritability and demographic analyses in the large isolated population of Val Borbera suggest advantages in mapping complex traits genes. PLoS One (2009) 1.11
Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med (2010) 1.10
Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood (2009) 1.10
Pathogenesis of ER storage disorders: modulating Russell body biogenesis by altering proximal and distal quality control. Traffic (2010) 1.10
Formation, isomerisation and reduction of disulphide bonds during protein quality control in the endoplasmic reticulum. Histochem Cell Biol (2002) 1.09
Molecular bases of cyclic and specific disulfide interchange between human ERO1alpha protein and protein-disulfide isomerase (PDI). J Biol Chem (2011) 1.09
Hemojuvelin N-terminal mutants reach the plasma membrane but do not activate the hepcidin response. Haematologica (2008) 1.08
A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands. J Mol Diagn (2004) 1.08
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods (2013) 1.08
Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer (2007) 1.08
Natural history of juvenile haemochromatosis. Br J Haematol (2002) 1.07
Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol (2005) 1.07
A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica (2010) 1.07
Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PLoS One (2012) 1.05